Metamark is leading a shift in urological cancer care to enable patients and their physicians to make informed tretment decisions that lead to better quality of life and lower cost of care.

LEARN MORE

Press Release

New Data Demonstrates ProMark™ Accurately Predicts Prostate Cancer Aggressiveness and Pathological Outcomes

ProMark™ has Potential to Transform Prostate Cancer Care by Aiding Doctors and Patients with Appropriate Treatment Assessment

read article
Press Release

METAMARK GENETICS RECEIVES LABORATORY LICENSE IN PREPARATION TO LAUNCH ProMark™ PROSTATE-CANCER ASSAY

Metamark Genetics, Inc. today announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company's prognostic assay to guide the medical management of patients with prostate cancer.

read article
Displaying results 11-12 (of 12)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 >  >|